Northern Institute for Cancer Research

Cancer Genomics

Cancer Genomics

The Institute of Genetic Medicine has state of the art facilities to investigate cancer at the genomic, transcriptomic and cell biological levels.

We are resourced with the region’s only single cell sequencing facility that couples single cell capture with next generation sequencing technologies.

Research includes investigation of tumour predisposition syndromes as a model to discover oncogenic dependencies and deliver interventional clinical trials for patient benefit. A landmark study reflecting this is CAPP3 where aspirin has been highlighted as a chemoprevention strategy in families with colorectal cancer predisposition due to mutations in DNA mismatch repair genes. Bioinformatic analysis of data from rare cancers has also led to the development of novel diagnostic tests in mismatch repair. Other research investigates cancer stem cells, kidney cancer, RNA splicing biology controls in prostate and breast cancer, the functions of microRNAs in breast cancer, and the biology of sugar modifications of both protein and lipids in prostate cancer. Clinical outputs from these research areas are instrumental to gain novel insights for prognostic and therapeutic benefit for patients. We have also have an active rare genetic disease group that partners with rare disease patients to carry out first in human interventions based on transcriptomic profiling of skin tumours, as well as a rare disease public engagement programme.